Drug-resistant pseudomonas aeruginosa phage composition and application
By developing Pseudomonas aeruginosa phage composition, the specificity and narrow bactericidal spectrum of the treatment of drug-resistant Pseudomonas aeruginosa infection in the prior art are solved, and efficient killing and stability of Pseudomonas aeruginosa is achieved. , broaden the application of treatment and purification.
Patent Information
- Application Number
- CN202410887633.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-03
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has problems such as strong specificity, narrow bactericidal spectrum and easy to tolerate bacteria in the treatment of drug-resistant Pseudomonas aeruginosa infection, resulting in the failure of widespread promotion of phage therapy.
A Pseudomonas aeruginosa phage composition was developed, including the phages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067 and CP-p-PA-23129, by isolating multiple The strains were used in combination to broaden the host profile and lysis capacity and improve the killing efficiency of Pseudomonas aeruginosa.
This phage composition significantly broadens the host spectrum, can effectively kill Pseudomonas aeruginosa, is not limited by whether the bacteria contain drug-resistant genes, has broad potential for clinical treatment and environmental purification, and has a large expansion in a short period of time , high titer and strong stability.
Smart Images

Figure CN118909968A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a drug-resistant Pseudomonas aeruginosa phage composition and application. Background Art
[0002] Pseudomonas aeruginosa, formerly known as Pseudomonas aeruginosa, is a representative species of the genus Pseudomonas. It is an obligately aerobic, non-fermentative, Gram-negative, single-flagellated bacillus that is widely found in natural environments such as water and soil, and in animals.
[0003] Pseudomonas aeruginosa is a common conditional pathogen in clinical practice and a major pathogen of nosocomial infection. It can cause bacteremia and sepsis, endocarditis, and infections of the respiratory tract, digestive tract, urinary tract, central nervous system, bones and joints, skin, and five sense organs. Susceptibility factors include: physical weakness, low immune function, trauma, intubation, surgery, transplantation, and use of ventilators.
[0004] Pseudomonas aeruginosa has an extremely complex resistance mechanism, including: low outer membrane permeability, biofilm formation, change in drug target, production of antibiotic-resistant enzymes (such as aminoglycosides and many β-lactams), active pumping system, etc. It is naturally resistant to most commonly used antibiotics in clinical practice, which brings great difficulties to clinical treatment. With the widespread and high-dose use of antibiotics, its isolation rate has been on the rise among non-fermenting bacteria.
[0005] Bacteriophage (phage) is a type of virus that uses specific microorganisms such as bacteria, fungi, actinomycetes or spirochetes as hosts. Similar to other viruses, the head of a bacteriophage is composed of a protein capsid that encapsulates genetic material. Tailed phages also have "tails" of varying lengths and shapes, which are used to specifically identify host bacteria and inject genetic material into the host. Compared with traditional antibiotics, phages have the advantages of strong bactericidal ability, high specificity, high safety, and low cost, and their bactericidal ability does not depend on bacterial resistance. Therefore, phages show great application potential in preventing and treating bacterial infections, especially drug-resistant bacterial infections.
[0006] Phages are undoubtedly a powerful weapon to control drug-resistant bacteria, and their application range is very wide. As early as more than 100 years ago, when phages were first discovered, some European countries had tried to use them to treat diseases such as dysentery. Later, due to the discovery and widespread use of antibiotics, many countries gave up phage therapy. As the problem of bacterial resistance becomes increasingly serious, phage therapy has regained attention. Many clinical cases of personalized phage treatment of drug-resistant bacterial infections have been carried out at home and abroad, demonstrating the great potential of phage therapy.
[0007] At present, phage personalized therapy has not been widely promoted, and there are no phage drugs on the market at home and abroad. Compared with traditional broad-spectrum antibiotics, phage therapy also faces the bottlenecks of strong specificity, narrow bactericidal spectrum and easy bacterial tolerance.
[0008] In view of the problems existing in the existing technology, it is necessary to conduct research on drug-resistant Pseudomonas aeruginosa phages and develop drug-resistant Pseudomonas aeruginosa phages with a wider lysis spectrum and more stable titer. Summary of the invention
[0009] The purpose of the present invention is to provide a drug-resistant Pseudomonas aeruginosa phage composition and application. Different natural phages have different host spectrum ranges, so the phage combination can break through the bottleneck of the above phage therapy to a certain extent, greatly broaden the host spectrum, and has broad application potential in clinical treatment of Pseudomonas aeruginosa infection and environmental purification.
[0010] The technical solution adopted by the present invention to solve the above technical problems is as follows:
[0011] The present invention provides a Pseudomonas aeruginosa phage, wherein the phage CP-p-PA-21006 has a preservation number of: CGMCC NO: 45793; the phage was deposited in the China General Microbiological Culture Collection Center on December 4, 2023, and was classified and named as the Myoviridae family.
[0012] The present invention also provides a Pseudomonas aeruginosa phage, the phage CP-p-PA-21013, the preservation number is: CGMCC NO: 45794; the phage was deposited in the China General Microbiological Culture Collection Center on December 4, 2023, and was classified and named Podoviridae.
[0013] The present invention also provides a Pseudomonas aeruginosa phage, the phage CP-p-PA-22067, with a preservation number of CCTCC M 20232436; the phage was deposited in the China Center for Type Culture Collection on December 4, 2023, with a preservation address of Wuhan University, Wuhan, China, and was classified and named Podoviridae.
[0014] The present invention also provides a Pseudomonas aeruginosa phage, the phage CP-p-PA-23125, with a deposit number of CCTCC M 20232438; the phage was deposited in the China Center for Type Culture Collection on December 4, 2023, with a deposit address of Wuhan University, Wuhan, China, and was classified and named Myoviridae.
[0015] The present invention also provides a Pseudomonas aeruginosa phage, the phage CP-p-PA-23129, with a deposit number of CCTCC M 20232437; the phage was deposited in the China Center for Type Culture Collection on December 4, 2023, with a deposit address of Wuhan University, Wuhan, China, and was classified and named Podoviridae.
[0016] The present invention also provides a Pseudomonas aeruginosa phage composition, which comprises a combination of any two or more of phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067, phage CP-p-PA-23125 or phage CP-p-PA-23129.
[0017] Furthermore, the Pseudomonas aeruginosa phage composition is preferably a combination of phage CP-p-PA-23129 and one or more of phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067 or phage CP-p-PA-23125.
[0018] The present invention also provides use of the Pseudomonas aeruginosa phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067, phage CP-p-PA-23125, phage CP-p-PA-23129 or Pseudomonas aeruginosa phage composition in preparing a preparation or medicine for preventing and treating Pseudomonas aeruginosa contamination.
[0019] The present invention also provides a preparation for preventing and treating Pseudomonas aeruginosa, wherein the preparation comprises bacteriophage CP-p-PA-21006, bacteriophage CP-p-PA-21013, bacteriophage CP-p-PA-22067, bacteriophage CP-p-PA-23125, bacteriophage CP-p-PA-23129 or the Pseudomonas aeruginosa phage composition.
[0020] Furthermore, the preparation may be an antimicrobial drug and / or an environmental disinfectant.
[0021] Furthermore, the preparation for preventing and treating Pseudomonas aeruginosa may be a drug for treating Pseudomonas aeruginosa infection.
[0022] Furthermore, the preparation for preventing and controlling Pseudomonas aeruginosa may be an environmental purifier for disinfecting Pseudomonas aeruginosa.
[0023] Compared with the prior art, the present invention has at least the following beneficial effects:
[0024] 1. The present invention isolates multiple strains of Pseudomonas aeruginosa phages (a total of 179 strains) from different environments, and uses 121 clinically resistant Pseudomonas aeruginosa strains from multiple hospitals in different regions of the country to analyze the lysis spectrum of the isolated 179 Pseudomonas aeruginosa phages, and finds that two of the Pseudomonas aeruginosa phages have obvious lysis advantages over other phages. Among them, Pseudomonas aeruginosa phages CP-p-PA-21013 and CP-p-PA-23129 can lyse 44 and 80 different Pseudomonas aeruginosa, respectively, and the lysis spectrum is significantly better than the prior art, and has great potential in clinical applications.
[0025] 2. The optimal infection multiplicity of the Pseudomonas aeruginosa phages CP-p-PA-21013, CP-p-PA-22067, and CP-p-PA-23129 provided by the present invention is 10 -5 Therefore, during the production process, only a very small amount of mother liquid or seed liquid is needed to amplify a large number of progeny phages, which has a high production efficiency; the optimal infection multiplicity of CP-p-PA-21006 is 10 0 ; The optimal infection multiplicity of CP-p-PA-23125 is 10 -2 The titers of phages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067, CP-p-PA-23125, and CP-p-PA-23129 were all over 1×10 9 PFU / mL; the lysis periods of bacteriophages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067, CP-p-PA-23125, and CP-p-PA-23129 were 25min, 50min, 10min, 15min, and 15min, respectively, and these phages could be amplified in large quantities in a short time, indicating that these phages have efficient lysis activity.
[0026] 3. The Pseudomonas aeruginosa phage provided by the present invention can specifically kill Pseudomonas aeruginosa, regardless of whether the bacteria contain drug-resistant genes.
[0027] 4. The Pseudomonas aeruginosa phage composition provided by the present invention broadens the host spectrum and lysis ability, and has broad application potential in clinical treatment of Pseudomonas aeruginosa infection and environmental purification.
[0028] 5. The present invention uses 121 clinical strains of Pseudomonas aeruginosa isolated from different regions, and conducts phage-host interaction analysis to provide a Pseudomonas aeruginosa phage composition. Compared with a single phage, the phage composition broadens the host spectrum that can be lysed and greatly improves the coverage rate.
[0029] 6. The Pseudomonas aeruginosa phage composition provided by the present invention broadens the phage lysis spectrum and enhances the lysis effect of phage on bacteria.
[0030] 7. The Pseudomonas aeruginosa phage provided by the present invention has strong stability and a wide tolerance temperature and pH range, which is conducive to the long-term stable storage of phage preparations. After being stored at 4°C for 6 months, the potency decreases by less than one order of magnitude. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a diagram of the phage purification results of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129.
[0032] Figure 2 The clustering results of the statistical analysis of the lysis spectra of 179 Pseudomonas aeruginosa phages against 121 clinically resistant Pseudomonas aeruginosa strains are shown in Figure 1. The horizontal direction is bacteria, and the vertical direction is phages.
[0033] Figure 3 The transmission electron microscopy results of the bacteriophages of the present invention are shown in Figure 1. A is bacteriophage CP-p-PA-21006, B is bacteriophage CP-p-PA-21013, C is bacteriophage CP-p-PA-22067, D is bacteriophage CP-p-PA-23125, and E is bacteriophage CP-p-PA-23129.
[0034] Figure 4 The figure is a result diagram of the optimal infection multiplicity of the Pseudomonas aeruginosa phage of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129.
[0035] Figure 5 The figure is a one-step growth curve of the Pseudomonas aeruginosa phage of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129.
[0036] Figure 6The temperature stability diagram of the Pseudomonas aeruginosa phage of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129.
[0037] Figure 7 The pH stability diagram of the Pseudomonas aeruginosa phage of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129. DETAILED DESCRIPTION
[0038] The technical solution of the present invention is described in detail below in conjunction with embodiments, but the protection scope of the present invention is not limited thereto.
[0039] Unless otherwise specified, the reagents and biological materials used below are commercial products.
[0040] (1) LB (Luria broth) liquid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.
[0041] (2) 0.5% LB semisolid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, agar powder 5 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.
[0042] (3) 1.5% LB solid medium (1 L): 10 g of peptone, 5 g of yeast powder, 10 g of NaCl, 15 g of agar powder, add ddH2O to 1 L, adjust the pH to 7.0, sterilize at 121°C for 20 min, cool to 50°C, pour into a plate, cool and solidify, and then invert for later use.
[0043] Example 1: Isolation of Pseudomonas aeruginosa phage
[0044] The sewage sample was collected from an environmental sewage in Shanghai. 20 mL of sewage sample was centrifuged at 4°C and 12000 rpm for 10 min. The supernatant was filtered with a 0.22 μm filter membrane and the filtrate was reserved. 9 mL of supernatant filtrate was added with 1 mL of 10×LB liquid culture medium and 0.1 mL of phage logarithmic phase host bacterial liquid, and placed at 37°C for shaking culture overnight. The next day, centrifuged at 4°C and 12000 rpm for 10 min, and the supernatant was filtered with a 0.22 μm filter membrane to sterilize, forming a stock solution containing phages, i.e., phage suspension.
[0045] Take different clinical drug-resistant strains and streak them on 1.5% LB solid medium. After culturing overnight at 37℃, pick a single clone and inoculate it in 5mL LB liquid medium. After shaking and culturing at 37℃ for 8h, use it as a host culture for standby. Take 0.3mL of the above standby host culture and 3mL0.5% LB semi-solid medium, mix them evenly and spread them on 1.5% LB solid medium. After solidification, divide the agar plate into 2 areas. Take 10μL of the above phage suspension and drop it on one area. Add an equal amount of PBS to the other area as a control. After drying naturally, place it in a 37℃ incubator for static culture, and observe whether there are plaques formed in the phage drop area. If plaques are formed, it proves that phages exist.
[0046] Example 2: Purification of Pseudomonas aeruginosa phage
[0047] Test method: Pick the phage plaques in Example 1 into a sterile EP tube filled with 0.5 mL PBS and place it at 4°C overnight to release the phages to obtain phage extract. Use the double-layer plate method to dilute the phage extract 10 times continuously and take out 10 -2 , 10 -4 , 10 -6 Add 0.3 mL of logarithmic phase host bacterial solution to 0.1 mL of diluent, add 3 mL of 0.5% LB semi-solid medium at about 55°C, evenly spread on a pre-prepared solid LB plate, and invert and culture at 37°C for 5-10 hours to obtain a double-layer plate with plaques. Pick a single transparent, uniform-sized, and regular-edged plaque again and put it into a sterile EP tube filled with 0.5 mL of PBS to obtain a phage extract. Repeat the above steps 3 times to obtain a purified phage suspension for later use.
[0048] Test results: Figure 1 It is a diagram of the phage purification results of the present invention, wherein A is phage CP-p-PA-21006, B is phage CP-p-PA-21013, C is phage CP-p-PA-22067, D is phage CP-p-PA-23125, and E is phage CP-p-PA-23129.
[0049] like Figure 1 As shown in the figure, bacteriophage CP-p-PA-21006 can form clear plaques in agar medium, with no halo around them, clear and regular edges, a diameter of about 1 mm, and a titer of 1.2×10 9 PFU / mL, which is a typical lytic phage.
[0050] Bacteriophage CP-p-PA-21013 can form clear plaques in agar medium, with no halo around them, clear and regular edges, a diameter of about 3 mm, and a titer of 1.1×10 10 PFU / mL, which is a typical lytic phage.
[0051] Bacteriophage CP-p-PA-22067 can form clear plaques in agar medium, with no halo around them, clear and regular edges, a diameter of about 1 mm, and a titer of 6.1×10 9 PFU / mL, which is a typical lytic phage.
[0052] Phage CP-p-PA-23125 can form clear plaques in agar medium, with no halo around them, clear and regular edges, a diameter of about 1.2 mm, and a titer of 1.3×10 9 PFU / mL, which is a typical lytic phage.
[0053] Phage CP-p-PA-23129 can form clear plaques in agar medium, surrounded by a halo, with clear and regular edges, a diameter of about 1.5 mm, and a titer of 7.6×10 9 PFU / mL, which is a typical lytic phage.
[0054] Example 3: Clustering and lysis spectrum analysis of Pseudomonas aeruginosa phage and bacteria
[0055] According to the lysis correspondence between phage and host, cluster analysis was performed on phage and bacteria respectively. Different objects clustered in the same cluster have great similarities, and objects in different clusters have great differences. The specific analysis process is as follows:
[0056] (1) First, 121 clinical resistant Pseudomonas aeruginosa strains from multiple hospitals in different regions of the country and 179 Pseudomonas aeruginosa phages isolated from different sewage were used for lysis spectrum analysis. The drug sensitivity results of some resistant strains among the 121 clinical Pseudomonas aeruginosa strains are shown in Table 1.
[0057] Table 1 Drug sensitivity results of Pseudomonas aeruginosa
[0058]
[0059]
[0060] Note: "R" represents that the bacteria are resistant to the antibiotic, "I" represents that the bacteria are moderately sensitive to the antibiotic, "S" represents that the bacteria are sensitive to the antibiotic, and the blank represents that the sensitivity of the bacteria to the antibiotic has not been tested.
[0061] The specific operations are as follows:
[0062] ① Take 0.3 mL of the logarithmic phase bacterial solution of Pseudomonas aeruginosa, add 3 mL of 0.5% LB semi-solid medium at about 55°C, and evenly spread it on the pre-prepared 1.5% LB solid medium;
[0063] ②Each plate was divided into two areas, 2 μL of the phage suspension prepared in Example 2 was dripped into one area, and an equal amount of PBS was dripped into the other area as a control, and after it was absorbed and dried, it was inverted and cultured at 37°C for 12 hours. Phage plaques are empty plaques formed by phage lysing bacteria on the plate, and they were divided into presence (+) and absence (blank) according to the presence or absence of phage plaques.
[0064] (2) The lysis spectrum results were statistically analyzed and classified into large and clear (LC), small and clear (SC), large and fuzzy (LO), small and fuzzy (SO), and no plaque (NP) according to the plaque morphology;
[0065] (3) Convert the symbol of the plaque transparency into a numerical value (0: no plaque NP, 1: blurred plaque O, 2: small and transparent plaque SC, 3: large and transparent plaque LC);
[0066] (4) Use RStudio software to load the R package functions for drawing;
[0067] (5) Analyze the generated clustering results.
[0068] Experimental results: The clustering results of the lysis spectrum of 179 Pseudomonas aeruginosa phages against 121 clinically resistant Pseudomonas aeruginosa are shown in Figure 2. According to the results of lysis spectrum and cluster analysis, phage CP-p-PA-23129 with a relatively broad host spectrum and complementary to each other was selected and combined with one or more of phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067 or phage CP-p-PA-23125 to form a phage cocktail. Table 2 shows the lysis spectrum results of the above five strains of Pseudomonas aeruginosa phages. Single phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067, phage CP-p-PA-23125 and phage CP-p-PA-23129 can lyse 22, 44, 3, 28 and 80 strains of Pseudomonas aeruginosa, respectively. Among them, the "cocktail" combination of phage CP-p-PA-23129 and one or more of the other four phages can lyse up to 88 strains of Pseudomonas aeruginosa, with a coverage rate of 73% (88 / 121). Compared with a single phage, the "cocktail" phage broadens the host spectrum that can be lysed and improves the coverage rate.
[0069] Table 2 Lysis spectrum of Pseudomonas aeruginosa phage against patient strains
[0070]
[0071]
[0072] Note: "+" represents that the bacteria were completely lysed by the phage, and the space represents that the bacteria could not be lysed by the phage.
[0073] Example 4: Expansion culture of Pseudomonas aeruginosa phage
[0074] Experimental method: Take 40 mL of LB liquid culture medium, add 0.4 mL of logarithmic host bacterial solution, place it in a 37°C shaker at 200 rpm and culture it for 1-2 hours until the logarithmic phase, then add 0.05 mL of the purified phage suspension in Example 2, continue to place it in a 37°C shaker at 200 rpm and culture it until the liquid in the test tube becomes clear, and then centrifuge and filter it for use.
[0075] The double-layer plate method was used to detect the phage titer: the above-mentioned reserved phage suspension was diluted 10 times in a gradient, 0.1 mL of the phage dilution solution in each gradient was taken and mixed with 0.3 mL of the host bacterial solution, and then spread on a double-layer agar plate. The plate was cultured at 37°C for about 5-10 hours, and the plaques were counted on each agar plate. The plate with about 30-300 plaques was selected, and the initial phage concentration, i.e., the phage titer, was calculated according to the dilution multiple.
[0076] Phage titer (PFU / mL) = number of plaques × dilution factor × 10.
[0077] Example 5: Transmission electron microscopy observation of Pseudomonas aeruginosa phage
[0078] Experimental method: Take the phage suspension in Example 4 for transmission electron microscopy observation, drop 10 μL of the purified phage suspension in Example 2 on a copper sheet, let it precipitate naturally for 10 minutes, absorb the excess liquid with filter paper, add a drop of 2% phosphotungstic acid (PTA, 2% w / v) for staining for 1-2 minutes, and observe using a transmission electron microscope after drying at room temperature.
[0079] Test results: Figure 3 It is the transmission electron microscopy result diagram of the bacteriophage of the present invention, wherein A is bacteriophage CP-p-PA-21006, B is bacteriophage CP-p-PA-21013, C is bacteriophage CP-p-PA-22067, D is bacteriophage CP-p-PA-23125, and E is bacteriophage CP-p-PA-23129.
[0080] Bacteriophage CP-p-PA-21006 has a regular icosahedral head with a diameter of about 78nm and a short, non-contractile tail of about 140nm. According to the "Taxonomy of Viruses: The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, bacteriophage CP-p-PA-21006 belongs to the Myoviridae family.
[0081] Bacteriophage CP-p-PA-21013 has a regular icosahedral head with a diameter of about 65nm and a short, non-contractible tail of about 40nm. According to the "Virus Classification - The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, bacteriophage CP-p-PA-21013 belongs to the Podoviridae family.
[0082] The bacteriophage CP-p-PA-22067 has a regular icosahedral head with a diameter of about 60nm and a long and retractable tail of about 20nm. According to the "Virus Classification - The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, the bacteriophage CP-p-PA-22067 belongs to the Podoviridae family.
[0083] Bacteriophage CP-p-PA-23125 has a regular icosahedral head with a diameter of about 75nm and a short, non-contractile tail with a length of about 140nm. According to the "Virus Classification - The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, bacteriophage CP-p-PA-23125 belongs to the Myoviridae family.
[0084] Bacteriophage CP-p-PA-23129 has a regular icosahedral head with a diameter of about 75nm and a long and retractable tail with a length of about 20nm. According to the "Taxonomy of Viruses - The Eighth Report of the International Committee on Taxonomy of Viruses" published by the International Committee on Taxonomy of Viruses (ICTV) in 2015, bacteriophage CP-p-PA-23129 belongs to the Podoviridae family.
[0085] Example 6: Whole genome extraction, sequencing and splicing analysis of Pseudomonas aeruginosa phage
[0086] Test method:
[0087] (1) Take 10 mL of each of bacteriophage CP-p-PA-21006, bacteriophage CP-p-PA-21013, bacteriophage CP-p-PA-22067, bacteriophage CP-p-PA-23125 and bacteriophage CP-p-PA-23129 in Example 4, add DNase I (10 U / μg) and RNase A (10 U / μg) with a final concentration of 1 μg / mL, mix thoroughly and incubate at 37° C. for 30 min;
[0088] (2) Add EDTA to a final concentration of 25 mM and incubate at 65°C for 10 min (to inactivate DNase);
[0089] (3) At the beginning of this step, nucleic acid was extracted using the M5λ phage genomic DNA rapid extraction kit;
[0090] (4) After verification by 1% agarose gel nucleic acid electrophoresis, the concentration and purity were determined by NanoDrop-300, and the product was sent to Shanghai Paisono Biotechnology Co., Ltd. for sequencing.
[0091] (5) The whole genome sequencing results of Pseudomonas aeruginosa phages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067, CP-p-PA-23125, and CP-p-PA-23129 were assembled and analyzed.
[0092] Experimental results: The results of whole genome sequencing showed that the complete genome size of Pseudomonas aeruginosa phage CP-p-PA-21006 was 66250bp, the complete genome size of Pseudomonas aeruginosa phage CP-p-PA-21013 was 43136bp, the complete genome size of Pseudomonas aeruginosa phage CP-p-PA-22067 was 44683bp, the complete genome size of Pseudomonas aeruginosa phage CP-p-PA-23125 was 66300bp, and the complete genome size of Pseudomonas aeruginosa phage CP-p-PA-23129 was 72279bp.
[0093] The specific sequences of Pseudomonas aeruginosa phages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067, CP-p-PA-23125, and CP-p-PA-23129 are shown in SEQ NOs 1 to 5, respectively.
[0094] SEQ NO 1: CP-p-PA-21006
[0095] agttctgggcgtgttcgactgcgacaaatctgcgaagtggtacagcaatgtgaaagacgcggttgttgattcctgggtagtggaatcgccgaacagctcgcgctcgcgcctctttaaaagagactgctataaagtcggggatcgcgtcatgtatc gcgatgagcatggagaagggtacggccgtatcttggctgtcgaacctcgcggcgaatcggcgcgtgacgagaaagagctgtatcacctgtaccagatcgaaagcaacgatccgtccgttgacatttggatgcttgacgcggacatcatcggcatt tatcccgacgaaaagcgctttacttctgacgagcagatggagtagaatctgctcacctaccaaagagggtgacgatatggaaagcatcacagtatggatcgccactgcttttctttgtactggcgatggctgtgtccagatgccggatcataccagcagacggtt
[0096] SEQ NO 2: CP-p-PA-21013
[0097] gtgtcccagcttcgctggccctcctggccgacggcctctgatccctggggatgggccggggcttccctgccctgtcgccgcccattctacgcatcctgccgggagtgtcaagcccctggtggggtggcggtccatcggctcatactcagcgccctgcggtgcgccaccagcgccagcctacggtcttccctggctctggctctggccgccgggtacgggctgtgctgctcatcctctgtcgcccacctggctagcttcctctgccatgctgcgtcgcgctggtgccaggctcgctcgcctctgtcctgtctgctcagcatcctctgtgcctcctggggcctctgccctctggtctggtggtggttgcgggagtggctagccttgcctcttgtggtattgcctcttgtggctctacctgggtactccctgggtggtcctggctctgcctggccactccctctaggccacgtactctactcgcctctacctgccttgtctagtcctgctccctgtcgcttcccggctctacctgtcgctccctgggtgctggtctacctccctggctctgtctggggcgctgcgctggtcctgcggtcttgcctcgccactccctcgcctgctcggtcgcacctgcggcgctga
[0098] SEQ NO 3:CP-p-PA-22067
[0099] tcaccaatcatggacgaaggtggatacgcccctgcaaatagcaaggtccacaaggaagttggccaggtcaaccctacgttgctctttacggatacgctcctcactaccgttgttcttcaggtagtagtggaggttgaaaagggagtcccgtaggaggttccgaggatcgaatgttttgtgacggtcaatgtagaagtcgtcatagaggctgagatccttgaggacaacccgttgttgcttcttggcggaataccgctctactttgccatgaccactaagataagtatagccaaggtagtttttgggcagcttgaagaagatgctacgggcagcctggaggggtactttgggattcatcagataggcttggatgagtttcttacgaatctcctccgccttagcttgggatagggcatcatttaccagcaggttacatgcgtaatgagattccatgtgtctctcctttagatataagagcaacccccggcaccacaaggttattataccacagaaagtaacttttgtcaagcccttttgtggaaaaccttgtcgtaccagcgatagaagtattgggcgaaggtaatccccagggcaccaccccaaccgctcacgaagatgaaccat
[0100] SEQ NO 4:CP-p-PA-23125
[0101] atgatagctcgacaagcccctttcgtctcaaagccttaagagtcaaattcgttggcgatctgtgaactggatgctcaggatgcctgtacatttccagtagaacggcatgctgccgaggactcagctttggactcagctttcccaaatcttccatatcattcacctcaattacagatggcgatgttgagaactttatcgcgcccggccgcgaacttctccaggaagtccaccaggtcattcaggatggtccccgctcgacctagcttgtggccgatcaggagctgcgcgactctgtgtccgacgaatttccccgaa ggaatcttcggccatgtttcgccgatgcttttgagtactgcatcagtgtagtctttgtc
[0102] SEQ NO 5: CP-p-PA-23129
[0103] gatgaggttgttctgcacgtctttctgctgaacgagcaggctgcccatgtaagcatgaacagaggcagcagcatcggagcgcaggaacgagtacaggctttcctggcgagctttcaactcgtccagttccagcttcagacgttccttcgcacccatccgctgcttgtgcagcttctgcatgagttcgtagccggcgaacttccacacctcgtcttccgcgttacgacgagcgacttcgattccgatctcggcatcgaattcatcggggtccacacaggatgactgcccggtgaccgtccagccgttgaccagggtaagctggcatacggtggtcagtccgctgggaaggatcgtgaaagactcttcca
[0104] Example 7: Determination of the Optimal Multiplicity of Infection (MOI) of Pseudomonas aeruginosa Phage
[0105] The multiplicity of infection (MOI) is the ratio of the number of phages to the number of bacteria.
[0106] Experimental method: (1) Take the host bacterial culture prepared in Example 1 and transfer it to the logarithmic phase (OD 600 nm=0.5), and adjust the concentration to 1×10 8 CFU / mL for later use; dilute the phage culture solution in Example 4 to 1×10 9 , 1×10 8 , 1×10 7 , 1×10 6 , 1×10 5 , 1×10 4 , 1×10 3 , 1×10 2 PFU / mL for standby use;
[0107] (2) According to the multiplicity of infection, 1 , 10 0 , 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 100 μL of the reserved phage dilution, 100 μL of the host bacterial culture and 5 mL of LB liquid medium were mixed evenly and cultured in a shaker at 37°C and 200 rpm for 5 h;
[0108] (3) Take 1 mL of lysate and centrifuge at 8000 rpm for 10 min at 4°C. Collect the supernatant and filter through a 0.22 μm filter membrane.
[0109] (4) Take 100 μL of the filtrate in step (3) and dilute it 10 times in a series;
[0110] (5) Take 100 μL of the diluent and mix it with 300-400 μL of the bacterial suspension. After standing for 5-10 min, add it to a 0.5% semi-solid culture medium cooled to about 55°C, mix it, spread it on a double-layer plate, and invert it in a 37°C constant temperature incubator for overnight culture;
[0111] (6) Observe the plate and calculate the phage titer. Repeat the experiment three times and draw a bar graph.
[0112] Test results: The results are as follows Figure 4 As shown, Figure 4 is the optimal infection multiplicity of the Pseudomonas aeruginosa phage of the present invention, and the optimal infection multiplicity of Pseudomonas aeruginosa phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067, phage CP-p-PA-23125 and phage CP-p-PA-23129 are 10 respectively. 0 , 10 -5, 10 -5 , 10 -2 , 10 -5 The average titer can reach 1.2×10 9 , 1.1×10 10 , 6.1×10 9 , 1.3×10 9 , 7.6×10 9 PFU / mL.
[0113] Example 8: One-step growth curve assay of Pseudomonas aeruginosa phage
[0114] Test method: One-step growth curve can reflect the replication characteristics of bacteriophage, including latent period and outbreak period. The specific method is as follows:
[0115] (1) Take the host bacterial culture prepared in Example 1 and transfer it to fresh culture medium at a ratio of 1:100, and add CaCl2 with a final concentration of 5 mmol / L to culture the bacteria to the logarithmic phase (OD 600 nm=0.5);
[0116] (2) Take 1 mL of the host bacteria cultured to the logarithmic growth phase, add the phage suspension prepared in Example 4 at a ratio of MOI = 0.1, mix well, and incubate in a 37° C. incubator for 5 min (to allow the bacteria to adsorb to the phage);
[0117] (3) Centrifuge at 10,000 rpm for 1 min at 4°C and discard the supernatant;
[0118] (4) Take 1 mL of fresh LB liquid and resuspend the pellet;
[0119] (5) Repeat steps (3) and (4), resuspending and washing at least twice;
[0120] (6) Finally, resuspend the pellet with 10 mL of fresh LB medium and incubate the resuspended test tube in a 37°C shaker at 200 rpm for 90 min. Samples were taken every 5 min (0, 5, 10, 15, 20, 25, 30 min) for the first 30 min, and then every 10 min (40, 50, 60, 70, 80, 90 min), taking out 600 μL of the culture mixture each time.
[0121] (7) Centrifuge at 4°C, 10,000 rpm for 1 min, collect the supernatant, and filter through a 0.22 μm filter membrane;
[0122] (8) Take 100 μL of phage filtrate and dilute it 10-fold;
[0123] (9) Take 100 μL of the diluent and mix it with 300-400 μL of the bacterial suspension. After standing for 5-10 min, add it to a 0.5% semi-solid culture medium cooled to about 55°C, mix it, spread it on a double-layer plate, and invert it in a 37°C constant temperature incubator for overnight culture;
[0124] (10) Observe the plate and calculate the phage titer. Repeat the experiment three times and draw a one-step growth curve.
[0125] Test results: The results are as follows Figure 5 As shown, Figure 5 The one-step growth curve of the phage of the present invention is shown in FIG. The latent periods of infection of the host bacteria by Pseudomonas aeruginosa phage CP-p-PA-21006, phage CP-p-PA-21013, phage CP-p-PA-22067, phage CP-p-PA-23125 and phage CP-p-PA-23129 are 5 min, 0 min, 10 min, 10 min, 5 min, respectively, and the outbreak periods are 25 min, 50 min, 10 min, 15 min, 15 min, respectively. The results show that the above phages can be amplified in large quantities in a short time, indicating that the above phages have efficient lytic activity.
[0126] Example 9: Temperature stability determination of Pseudomonas aeruginosa phage
[0127] Test method: In order to detect the temperature stability of isolated bacteriophages, this study set 8 temperature values (4-80°C), the specific method is as follows:
[0128] (1) Take 10 sterile 1.5 mL centrifuge tubes and number them as follows: 4°C, 25°C, 37°C, 40°C, 50°C, 60°C, 70°C, 80°C;
[0129] (2) Add 1 mL of phage stock solution to each centrifuge tube and place the corresponding numbered phage stock solutions in 8 different temperature environments for 60 min;
[0130] (3) Take 100 μL of the phage stock solution at each temperature after treatment and perform a 10-fold gradient dilution to 10 -7 times;
[0131] (4) Select three dilutions with appropriate dilution multiples according to different temperatures for plating, and culture the double-layer agar plates overnight;
[0132] (5) Select a plate with an appropriate number of plaques (30 to 300 plaques) to calculate the phage titer. Repeat the above test 3 times.
[0133] Test results: The results are as follows Figure 6 As shown, Figure 6The temperature stability of the bacteriophage of the present invention is that the titer of Pseudomonas aeruginosa phage CP-p-PA-21006 remains stable when the temperature is ≤50°C, the titer gradually decreases when the temperature is greater than 60°C, and the phage is inactivated when the temperature is increased to 80°C; the titer of bacteriophage CP-p-PA-21013 and bacteriophage CP-p-PA-22067 remains stable when the temperature is ≤50°C, the titer gradually decreases when the temperature is greater than 60°C, and the phage is inactivated when the temperature is increased to 70°C; the titer of bacteriophage CP-p-PA-23125 remains stable when the temperature is ≤60°C, the titer gradually decreases when the temperature is greater than 60°C, and the phage is inactivated when the temperature is increased to 70°C; the titer of bacteriophage CP-p-PA-23129 remains stable when the temperature is ≤40°C, the titer gradually decreases when the temperature is greater than 50°C, and the phage is inactivated when the temperature is increased to 60°C. It can be seen from this that the bacteriophage in the present invention has good temperature stability and can withstand a certain degree of high temperature.
[0134] Example 10: pH stability determination of Pseudomonas aeruginosa phage
[0135] Test method: In order to detect the acid-base stability of isolated phages, 11 pH values (pH = 2-12) were set in this study. The specific method is as follows:
[0136] (1) Prepare solutions with pH values of 2 to 12 using sterile PBS buffer, sodium hydroxide, and concentrated hydrochloric acid. Aliquot 0.9 mL into 1.5 mL centrifuge tubes for later use.
[0137] (2) Take 100 μL of purified and filtered phage solution (adjust the titer to 1×10 9 PFU / mL) were added to 0.9 mL of sterile PBS buffer of various pH values (pH 2-12), vortexed to mix, and placed in a 37°C constant temperature incubator for 1 h;
[0138] (3) Take out the 1.5 mL centrifuge tubes at each pH value, take 100 μL of phage solution from the 1.5 mL centrifuge tubes after each pH value treatment, and perform 10-fold gradient dilution to 10 -6 times;
[0139] (4) Select three dilutions of appropriate dilution multiples for plating and incubate the double-layer agar plates overnight;
[0140] (5) Select a plate with an appropriate number of plaques (30 to 300 plaques) to count the number of plaques at different pH values and calculate the phage titer. Repeat the above test 3 times.
[0141] Test results: The results are as follows Figure 7 As shown, Figure 7The pH stability of the phage of the present invention is that the titer of Pseudomonas aeruginosa phage CP-p-PA-21006 remains stable at pH 3-10, the titer of phage CP-p-PA-21013 and phage CP-p-PA-22067 remains stable at pH 4-10, the titer of phage CP-p-PA-23125 remains stable at pH 3-11, and the titer of phage CP-p-PA-23129 remains stable at pH 4-11; when the pH value is 2-3 or 11-12, the titer of the above phages gradually decreases; when the pH value is greater than 12, the above phages are inactivated; especially, a small amount of phage CP-p-PA-21006 and phage CP-p-PA-23125 still survive at pH 2. It can be seen that the phage of the present invention has good acid-base stability and can tolerate a certain degree of strong acid and strong base.
[0142] The above are only some preferred embodiments of the present invention, and the present invention is not limited to the contents of the embodiments. For those skilled in the art, various changes and modifications can be made within the scope of the technical solution of the present invention, and any changes and modifications made are within the protection scope of the present invention.
Claims
1. A Pseudomonas aeruginosa phage, characterized in that: The bacteriophage CP-p-PA-23129 is deposited in the China Center for Type Culture Collection with the deposit number: CCTCC M 20232437 and the deposit date is December 4, 2023.
2. A Pseudomonas aeruginosa phage, characterized in that: The bacteriophage CP-p-PA-21006 is deposited in the China General Microbiological Culture Collection Center with the deposit number: CGMCC NO: 45793 and the deposit date is December 4, 2023.
3. A Pseudomonas aeruginosa phage, characterized in that: The bacteriophage CP-p-PA-21013 is deposited in the China General Microbiological Culture Collection Center with the deposit number: CGMCC NO: 45794 and the deposit date is December 4, 2023.
4. A Pseudomonas aeruginosa phage, characterized in that: The bacteriophage CP-p-PA-22067 is deposited in the China Center for Type Culture Collection with the deposit number: CCTCC M 20232436 and the deposit date is December 4, 2023.
5. A Pseudomonas aeruginosa phage, characterized in that: The bacteriophage CP-p-PA-23125 is deposited in the China Center for Type Culture Collection with the deposit number: CCTCC M 20232438 and the deposit date is December 4, 2023.
6. A Pseudomonas aeruginosa phage composition, characterized in that: The phage composition comprises any two or more combinations of phage CP-p-PA-21006 according to claim 2, phage CP-p-PA-21013 according to claim 3, phage CP-p-PA-22067 according to claim 4, phage CP-p-PA-23125 according to claim 5, or phage CP-p-PA-23129 according to claim 1.
7. The Pseudomonas aeruginosa phage composition according to claim 6, characterized in that: The composition includes bacteriophage CP-p-PA-23129 and one or more of the following bacteriophages: bacteriophage CP-p-PA-21006, bacteriophage CP-p-PA-21013, bacteriophage CP-p-PA-22067 or bacteriophage CP-p-PA-23125.
8. The Pseudomonas aeruginosa phage composition according to claim 6, characterized in that: The specific sequences of Pseudomonas aeruginosa phages CP-p-PA-21006, CP-p-PA-21013, CP-p-PA-22067, CP-p-PA-23125, and CP-p-PA-23129 are shown in SEQ NOs 1 to 5, respectively.
9. Use of the Pseudomonas aeruginosa phage according to any one of claims 1 to 5 or the Pseudomonas aeruginosa phage composition according to claim 6 or 7 in the preparation of a preparation or medicine for preventing and treating Pseudomonas aeruginosa contamination.
10. A preparation for preventing and treating Pseudomonas aeruginosa, characterized in that: The preparation comprises the Pseudomonas aeruginosa phage according to any one of claims 1 to 5 or the Pseudomonas aeruginosa phage composition according to claim 6 or 7.
Citation Information
Patent Citations
Cleavable multiple-drug resistant pseudomonas aeruginosa bacteriophage and application thereof in infection treatment
CN104140957A
Drug-resistant coli phage and application thereof
CN109251899A
Pseudomonas aeruginosa phage and application thereof
CN110144333A
Pseudomonas aeruginosa phage composition, phage preparation and application thereof
CN118147088A
LYTIC BACTERIOPHAGE SPECIFIC FOR ACINETOBACTER GENUS RESISTANT TO CARBARPENEM
KR1020130129326A
